The Trump administration’s push to lower U.S. drug prices through direct deals with major pharmaceutical companies — including Pfizer, AstraZeneca, and EMD Serono — has drawn scrutiny over its transparency and impact.

President Donald Trump announced a deal with AstraZeneca aimed at lowering drug costs through “Most Favored Nation” pricing — following a similar agreement with Pfizer. Both drugmakers agreed to sell select medications at discounted rates and join the new TrumpRx online platform, offering direct-to-consumer discounts.

Tom Keene highlights the Single Best Idea from the latest Bloomberg Surveillance Radio, featuring insights from Henrietta Treyz and Aakash Doshi.

With just weeks left before the government funding deadline, attention is shifting to how voters might assign blame if lawmakers fail to reach a deal.

Congress faces a looming Sept. 30 funding deadline with just 16 calendar days left — and fewer than half of those scheduled for House and Senate sessions. Anxiety is rising as lawmakers head toward the fiscal year’s end without a full funding plan.

Henrietta Treyz, co-founder of Veda Partners, joined Bloomberg Surveillance to break down the latest policy moves in Washington.

Henrietta explained that a current court case questions the president’s authority under IEEPA to maintain tariffs (like those imposed on India). A ruling from the appeals court could come soon.

Fed rate cuts on the horizon? 📉 Veda Partners' Henrietta Treyz breaks down the likelihood of a September interest rate cut, the impact of new trade tariffs

President Trump is again urging Federal Reserve Chairman Jerome Powell to cut rates, posting on Truth Social, "Jerome “Too Late” Powell must NOW lower the rate... The damage he has done by always being Too Late is incalculable." Veda Partners director of economic policy Henrietta Treyz says the post suggests that Trump "knows he's living on borrowed time with the inflation that will come from his tariffs." Hear more from her in the video above.